Jump to main content
Jump to site search

Issue 3, 2013
Previous Article Next Article

Prenyltransferase inhibitors: treating human ailments from cancer to parasitic infections

Author affiliations

Abstract

The posttranslational modification of protein prenylation is a covalent lipid modification on the C-terminus of substrate proteins that serves to enhance membrane affinity. Oncogenic proteins such as Ras have this modification and significant effort has been placed into developing inhibitors of the prenyltransferase enzymes for clinical therapy. In addition to cancer therapy, prenyltransferase inhibitors have begun to find important therapeutic uses in other diseases, including progeria, hepatitis C and D, parasitic infections, and other maladies. This review will trace the evolution of prenyltransferase inhibitors from their initial use as cancer therapeutics to their expanded applications for other diseases.

Graphical abstract: Prenyltransferase inhibitors: treating human ailments from cancer to parasitic infections

Back to tab navigation

Publication details

The article was received on 04 Oct 2012, accepted on 24 Nov 2012 and first published on 27 Nov 2012


Article type: Review Article
DOI: 10.1039/C2MD20299A
Med. Chem. Commun., 2013,4, 476-492

  •   Request permissions

    Prenyltransferase inhibitors: treating human ailments from cancer to parasitic infections

    J. D. Ochocki and M. D. Distefano, Med. Chem. Commun., 2013, 4, 476
    DOI: 10.1039/C2MD20299A

Search articles by author

Spotlight

Advertisements